After eight years of supporting major autism campaign causes, funding education for the less priviledged, charitable visits to orphanages and prisons amongst others...
the Arise Monalisa Foundation has embarked on the Uterine Fibroid Project, this year, aimed at creating awareness, sensitizing the populace and sponsoring treatment of infected women across the country.
Monalisa Chinda, Arise Monalisa foundation Founder |
Speaking during the meeting which held on Wednesday 14th January 2015 at NAFDAC's headquarters in Abuja, Monalisa Chinda, multi-gifted actress and Founder of AMF said, "It is in giving our lives away that we find meaning... We appreciate NAFDAC for this strategic partnership as we look forward to propagating awareness of this fast spreading yet widely neglected uterine fibroid, which has become very common among women due to ignorance and stigmatization."
Director General (DG) NAFDAC Paul Orhii |
According to Dr. Paul
Orhii, Director General, NAFDAC, "We are proud to partner with the Arise Monalisa Foundation in
mobilizing this timely project throughout
the six geo-political zones in Nigeria, and this also marks the flag-off of our projects for this year."
NAFDAC hosts the Arise Monalisa Foundation team |
NAFDAC hosts the Arise Monalisa Foundation team |
Established in 1993, the National Agency for Food and Drug Administration and Control (NAFDAC) is responsible for regulating and controlling the manufacture, importation, exportation, advertisement,
distribution, sales and use of food, drugs, cosmetics, medical services, chemicals and packaged water. The current director-general of NAFDAC, Paul Orhii, holds a PhD in medicine.
Abubakar Jimoh, Director Special Duties NAFDAC |
Director General (DG) NAFDAC Paul Orhii presents to Monalisa Chinda |
Founded by multi-award winning actress Monalisa Chinda, the Arise Monalisa Foundation (AMF) is an Africa-based not-for-profit institution dedicated to inspiring hope, promoting creativity and creating opportunities for the less priviledged across the continent.
No comments:
Post a Comment